GILEAD SCIENCES, INC. Tax Adjustments, Settlements, and Unusual Provisions
GILEAD SCIENCES, INC. (GILD) reported Tax Adjustments, Settlements, and Unusual Provisions of -$91.00 million for the 3-month period ending 2020-09-30, per its 10-Q filed 2020-11-04.
Discontinued › Notes › Income Taxes
us-gaap:TaxAdjustmentsSettlementsAndUnusualProvisions · last filed 2022-02-23
- GILEAD SCIENCES, INC. tax adjustments, settlements, and unusual provisions for the quarter ending 2020-09-30 was -$91.00M.
- GILEAD SCIENCES, INC. tax adjustments, settlements, and unusual provisions for the quarter ending 2019-12-31 was $114.00M.
- GILEAD SCIENCES, INC. tax adjustments, settlements, and unusual provisions for the quarter ending 2019-09-30 was $0.00, a 100.00% decline year-over-year.
- GILEAD SCIENCES, INC. tax adjustments, settlements, and unusual provisions for the quarter ending 2019-06-30 was $0.00.
- GILEAD SCIENCES, INC. tax adjustments, settlements, and unusual provisions for fiscal 2019 was $114.00M.
| Period end | Tax Adjustments, Settlements, and Unusual Provisions 3 month | Tax Adjustments, Settlements, and Unusual Provisions 6 month | Tax Adjustments, Settlements, and Unusual Provisions 6 month as first filed | Tax Adjustments, Settlements, and Unusual Provisions 9 month | Tax Adjustments, Settlements, and Unusual Provisions 12 month |
|---|---|---|---|---|---|
| 2020-09-30 | -$91.00M 10-Q · filed 2020-11-04 | ||||
| 2019-12-31 | $114.00M 10-K · filed 2020-02-25 | $114.00M derived: sum of 2 quarters · filed 2020-11-04 | $114.00M derived: sum of 3 quarters · filed 2020-11-04 | $114.00M 10-K · filed 2022-02-23 | |
| 2019-09-30 | $0.00 derived: 10-Q 9 month − 10-Q 6 month · filed 2020-11-04 | $0.00 derived: sum of 2 quarters · filed 2020-11-04 | -$119.00M 10-Q · filed 2020-11-04 | ||
| 2019-06-30 | $0.00 derived: 10-Q 6 month − 10-Q 3 month · filed 2020-08-06 | -$119.00M 10-Q · filed 2020-08-06 | |||
| 2019-03-31 | -$119.00M 10-Q · filed 2020-05-06 | ||||
| 2018-09-30 | $355.00M derived: 10-Q 9 month − 10-Q 6 month · filed 2018-11-06 | $153.00M derived: sum of 2 quarters · filed 2019-08-06 | $202.00M 10-Q · filed 2018-11-06 | ||
| 2018-06-30 | -$202.00M 10-Q · filed 2019-08-06 | -$153.00M 10-Q · filed 2019-11-05 | $202.00M 10-Q · filed 2018-08-06 | ||
| 2018-03-31 | $49.00M 10-Q · filed 2019-05-08 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| AMGEN INC (AMGN) | United States | $219.567B | 22.39 |
| Moderna, Inc. (MRNA) | United States | $77.819B | -8.86 |
| Revolution Medicines, Inc. (RVMD) | United States | $42.805B | -22.69 |
| BIOGEN INC. (BIIB) | United States | $33.427B | 19.60 |
| EXELIXIS, INC. (EXEL) | United States | $14.358B | 16.15 |
| NEUROCRINE BIOSCIENCES INC (NBIX) | United States | $14.131B | 24.25 |
| HALOZYME THERAPEUTICS, INC. (HALO) | United States | $13.083B | 21.59 |
| Twist Bioscience Corp (TWST) | United States | $11.540B | -47.21 |
| BIO-TECHNE Corp (TECH) | United States | $11.379B | 74.68 |
| REPLIGEN CORP (RGEN) | United States | $10.755B | 185.31 |